
Read More
Stocks to Watch Tomorrow...
Drug approval, a strategic acquisition and a Rs 359 crore railway contract have put Emcure, Krishca ...

Drug approval, a strategic acquisition and a Rs 359 crore railway contract have put Emcure, Krishca ...

Emcure Pharmaceuticals will expand the use of Poviztra® for the treatment of MASH following CDSCO ap...

Emcure Pharmaceuticals is acquiring the entire 12.05 per cent minority stake in Gennova Biopharmaceu...

Fresh defence orders, a major pharma restructuring and a new government contract could keep BEL, Emc...

Board to Consider Audited Q4FY26 Results and Final Dividend on 5 May; Public Shareholding Rises to 1...

Emcure Pharmaceuticals cuts prices of its semaglutide injection Poviztra®, making weight management ...

The stock price has surged over 53.21 per cent in the last 1 year and delivered approximately 68.41 ...

The stock is trading at 0.65 times its book value and the stock is up by 36 per cent from its 52-wee...

The stock is up by 20 per cent from its 52-week low of Rs 911.75 per share....

The company’s shares have delivered an impressive return of around 30 per cent to its shareholders....